(Reuters) - Actos, the main earnings engine for Japan's largest drug
maker, has seen its fortunes rise after sales of
GlaxoSmithKline's Avandia slumped following a critical
study by top cardiologist Steven Nissen published on May 21.
Takeda said April-June first-quarter net profit climbed to
131 billion yen on a 9.6 percent rise in revenue from a year
earlier to 366 billion yen.
Read more at Reuters.com Market News
maker, has seen its fortunes rise after sales of
GlaxoSmithKline's Avandia slumped following a critical
study by top cardiologist Steven Nissen published on May 21.
Takeda said April-June first-quarter net profit climbed to
131 billion yen on a 9.6 percent rise in revenue from a year
earlier to 366 billion yen.
Read more at Reuters.com Market News
No comments:
Post a Comment